ProfileJobs

Curis

Healthbiotechdrug developmenthealthtechoncology

Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical studies in patients with lymphomas and solid tumors. It is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, the Company has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. 

Revenue(Q1, 2017)
$2.1 M
Market capitalization(2017-08-15)
$264.6 M
Company Growth (employees)
Type
Public
HQ
Lexington, US
Founded
2000
Size (employees)
58 (est)+32%
Website
curis.com
Curis was founded in 2000 and is headquartered in Lexington, US

Curis Office Locations

Curis has an office in Lexington
Lexington, US (HQ)
4 Maguire Rd

Curis Data and Metrics

Curis Financial Metrics

Curis's revenue was reported to be $2.1 m in Q1, 2017
USD

Revenue (Q1, 2017)

2.1 m

Net income (Q1, 2017)

(15.7 m)

EBIT (Q1, 2017)

(15.1 m)

Market capitalization (15-Aug-2017)

264.6 m

Cash (31-Mar-2017)

42.4 m
Curis's current market capitalization is $264.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

15 m9.8 m7.9 m7.5 m

Revenue growth, %

(34%)(20%)(4%)

Operating expense total

24.4 m25.7 m64.4 m65.6 m

EBIT

(9.4 m)(15.9 m)(56.5 m)(58 m)

EBIT margin, %

(63%)(161%)(717%)(771%)

Interest expense

3.8 m3.7 m3.3 m2.8 m

Interest income

164.7 k165.1 k277.3 k406 k

Net Income

(12.3 m)(18.7 m)(59 m)(60.4 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

4.8 m1.8 m1.7 m2.1 m2 m1.7 m1.7 m1.8 m2.1 m

R&D expense

3.3 m3.7 m4.7 m5.9 m4 m6.8 m8.8 m6.8 m13.5 m

General and administrative expense

2.9 m2.7 m3.5 m3.4 m2.8 m3.6 m3.4 m4.7 m3.5 m

Operating expense total

6.3 m6.4 m8.2 m9.3 m6.8 m10.4 m12.3 m11.5 m17.1 m

EBIT

(1.5 m)(31 m)(7.4 m)(4.8 m)(8.8 m)(10.7 m)(27.8 m)(15.1 m)

EBIT margin, %

(32%)(1871%)(354%)(237%)(510%)(636%)(1580%)(706%)

Interest expense

(949.7 k)(933.9 k)(866.9 k)(843.4 k)(826.7 k)(739.8 k)(729 k)(657 k)(656 k)

Interest income

41.5 k38.9 k40.3 k84.1 k127.3 k105.2 k119 k101 k70 k

Net Income

(1.9 m)(5.6 m)(31.8 m)(8.1 m)(5.5 m)(9.4 m)(11.3 m)(28.3 m)(15.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9.6 m7.7 m33.1 m26 m

Accounts Receivable

1.5 m2 m2.1 m2.5 m

Inventories

495.3 k489.8 k1.2 m1.3 m

Current Assets

60.2 m52.2 m85.5 m48.2 m

PP&E

445.7 k407.7 k277.7 k413 k

Goodwill

9 m9 m9 m9 m

Total Assets

80.6 m62.6 m95 m57.8 m

Accounts Payable

2 m2.3 m4.2 m5.9 m

Current Liabilities

6.6 m10.1 m10.8 m13.5 m

Total Liabilities

28.5 m

Additional Paid-in Capital

806.7 m810 m903.2 m928.3 m

Retained Earnings

(760.8 m)(779.6 m)(838.5 m)(898.9 m)

Total Equity

45.2 m29.8 m64.5 m29.3 m

Financial Leverage

1.8 x2.1 x1.5 x2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

10.2 m7.9 m23.5 m31.5 m28.7 m14.7 m8.6 m20.7 m42.4 m

Accounts Receivable

4.8 m1.8 m1.8 m2.1 m2.3 m1.7 m1.9 m1.9 m2.2 m

Current Assets

61 m57.1 m102.6 m102.1 m96.6 m75.8 m64.5 m56.6 m64.4 m

PP&E

439.4 k407.4 k364 k323.1 k315.5 k383.6 k451 k406 k410 k

Goodwill

9 m9 m9 m9 m9 m9 m9 m9 m9 m

Total Assets

73.9 m68.2 m119.3 m111.6 m106.1 m85.3 m74.1 m66.2 m73.8 m

Accounts Payable

2.8 m2.4 m2.8 m2.4 m2.6 m4.9 m3.9 m5.1 m5.9 m

Current Liabilities

9.9 m9.8 m9.7 m9 m9.3 m11.9 m11.3 m12.5 m11 m

Additional Paid-in Capital

808.3 m809.2 m899.3 m900.3 m901.2 m904.1 m905.6 m925.6 m936.2 m

Retained Earnings

(768.3 m)(773.9 m)(811.4 m)(819.5 m)(825.1 m)(848 m)(859.3 m)(887.6 m)(914.7 m)

Total Equity

39.4 m34.6 m87.6 m80.6 m76 m55.9 m46.2 m37.9 m21.5 m

Financial Leverage

1.9 x2 x1.4 x1.4 x1.4 x1.5 x1.6 x1.7 x3.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(12.3 m)(18.7 m)(59 m)(60.4 m)

Depreciation and Amortization

141.5 k155.1 k160.8 k193 k

Accounts Receivable

(569.1 k)(483.8 k)(145 k)(353 k)

Cash From Operating Activities

(9.5 m)(16.8 m)(29.9 m)(35.8 m)

Cash From Investing Activities

(13.6 m)16.3 m(6.4 m)30.1 m

Cash From Financing Activities

20 m(1.3 m)61.7 m(1.4 m)

Interest Paid

2.9 m4.4 m3.3 m2.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.9 m)(5.6 m)(31.8 m)(8.1 m)(5.5 m)(9.4 m)(11.3 m)(28.3 m)(15.7 m)

Accounts Receivable

4.8 m1.8 m1.8 m2.1 m2.3 m1.7 m1.9 m1.9 m2.2 m

Accounts Payable

2.8 m2.4 m2.8 m2.4 m2.6 m4.9 m3.9 m5.1 m5.9 m
USDY, 2017

Revenue/Employee

41.8 k

Financial Leverage

3.4 x

Curis Market Value History

Market Position of Curis

Competitors

ImmunoGen
Health - Public
Heat Biologics
Health - Public
XBiotech
Health - Public
Immune Design
Health - Public
Compare competitors

Traffic Overview of Curis

Curis Online and Social Media Presence

Curis Company Life and Culture

You may also be interested in